AsianScientist (Nov. 30, 2016) – WuXi Biologics, a WuXi AppTec group company, and Prima Biomed Ltd. (Prima) have signed a non-binding Memorandum of Understanding to form a strategic biologics development and manufacturing partnership.
WuXi Biologics is an open-access technology capability and technology platform that enables companies to develop biologics. Prima is a globally active biotechnology company that develops immunotherapeutic products for the treatment of cancer.
Under the partnership, WuXi Biologics will be Prima’s exclusive clinical manufacturer worldwide for IMP321, a protein developed by Prima for use in oncology. This agreement excludes any manufacturing for supply to the China, Macau, Taiwan and Hong Kong markets, where rights are retained by Prima’s development partner in China, Eddingpharm.
IMP321, a first-in-class soluble LAG-3 Ig fusion protein and an antigen presenting cell activator boosting T-cell responses for cancer chemo-immunotherapy, is currently in Phase II trials in Europe.
———
Source: WuXi AppTec; Photo: Pexels.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
